✦ LIBER ✦

1262 Safety of the phase III randomized study of HYMITAQ vs. doxorubicin in unresectable hepatocellular carcinoma (HCC): ETHECC trial (Evaluation of thymitaq in HCC) vs. safety of the phase II program with THYMITAQ

✍ Scribed by GISH, R

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

3535 POSTER Phase II trial investigating

✍ S.J. Faivre; E. Raymond; J. Douillard; E. Boucher; H.Y. Lim; J.S. Kim; S. Lanzal 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 61 KB

6519 Efficacy and safety of sorafenib in

✍ Llovet, J.; Cheng, A.; Qin, S.; Shan, M.; Nadel, A.; Burock, K.; Forner, A.; Zou 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 47 KB

6010 A three-arm phase III randomized tr

✍ Hoff, P.; Clarke, S.; Cunningham, D.; Van Cutsem, E.; Moore, M.; Schmoll, H.J.; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

373 EVALUATION OF THE EFFICACY AND SAFET

✍ P. Ciammella; P. Gontero; A. Tizzani; U. Ricardi; F. Valentino 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 509 KB

7012 Evaluation of the efficacy and safe

✍ Ciammella, P.; Badellino, S.; Botticella, A.; Filippi, A.r.; Valentino, F.; Gont 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB